Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Neal Walker is Director at Aldeyra Therapeutics. OQRO lists 2 transactions filed with the SEC under this name, the latest on Jun 11, 2026, each linked to the official Form 4.
Director
Disclosures on record
2
Companies involved
1
Aldeyra TherapeuticsALDX
2 disclosures · Jun 2026
Jun 9, 202670Kdisclosed Jun 11
DetailsOfficial recordJun 9, 20263,318disclosed Jun 11
DetailsOfficial recordNeal Walker bought shares on the open market in 2014 and 2018, and has not bought since 2018 across 2 companies. Sales in 3 of the 13 years since 2014.
Neal Walker reported 2 open-market purchases and 18 sales since 2014; purchases in 2 different years, most recently 2018.
| Year | Bought | Sold |
|---|---|---|
| 2023 | — | $1.85M10×10 trades |
| 2022 | — | $2M5×5 trades |
| 2021 | — | $1.52M3×3 trades |
| 2018 | $168K1×1 trade | — |
| 2014 | $50K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Neal Walker bought shares on the open market in 2014 and 2018, and has not bought since 2018 across 2 companies. Sales in 3 of the 13 years since 2014.
In SEC filings since 2014: the latest open-market purchase is from 2018; the latest open-market sale is from 2023.
2 companies: Aclaris Therapeutics (ACRS, 2018–2023), Aldeyra Therapeutics (ALDX, 2014).
Neal Walker reported 1 open-market purchase and 18 sales here, 2018 to 2023.
Neal Walker reported 1 open-market purchase and 0 sales here, 2014.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
